

INTRATUMORAL TREATMENT OF MULTIPLE CANINE MAST CELL TUMOURS WITH TIGILANOL TIGLATE (STELFONTA®)

OBJECTIVES

An open field clinical study reported the use of intratumoral administration of tigilanol tiglate for the treatment of up to 3 mast cell tumours (MCT) on the same dog.

MATERIALS & METHODS


- **Animals:**
 - 18 dogs, with 43 MCT confirmed by fine needle aspiration cytology.
- **Treatment administration:**
 - Concurrent medications: Corticosteroids, H1 & H2 blockers.
 - Tigilanol tiglate: 0.5mg of tigilanol tiglate delivered per cm³ of MCT volume (with maximum dose per patient ≤ 0.25ml/kg and a maximum total dose ≤ 5mg).
- **Evaluations:**
 - Tumour response at day 28.
 - Clinical evaluations at day 1, 7, 14, 28, 84, 180.

RESULTS

- **Day 28: 93% (40/43) tumours with complete response, and 83% (15/18) dogs with complete response**
- **6 months: 97% (34/35) tumours were local recurrence free and 87% (13/15) dogs had no local recurrence at treatment site**
- **The majority (84%) of adverse events were expected due to the mode of action of tigilanol tiglate and all were mild to moderate.**

CLINICAL INTEREST

Tigilanol tiglate is safe and show endured efficacy (6 months follow-up) for concurrent treatment of multiple MCTs.



REFERENCES

Campbell JE, Jones PD, Brown GK, De Ridder TR, Reddell P. Concurrent intratumoral treatment of multiple canine mast cell tumors with the novel small molecule tigilanol tiglate (EBC-46). ACVIM Forum 2020, 017. <https://www.eventscribe.com/2020/ACVIM/PosterTitles.asp?pfp=PosterTitles>.